Alternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL

Alternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL

(MedPage Today) -- CHICAGO -- Late-phase trials that showed superiority for an experimental intervention on a surrogate endpoint did not necessarily lead to improvements in overall survival (OS) or quality of life (QOL), according to a meta-epidemiologic...

Surrogate Endpoints in Cancer: Balancing Speed and Uncertainty

In the relentless quest to better understand and treat cancer, the concept of surrogate end points has surfaced as a double-edged sword within the realm of clinical oncology trials. These markers, which serve as proxies for true clinical outcomes, promise to accelerate the drug approval process and potentially deliver